$39.14
+2.22%Oct 29, 2026, 15:02 UTC
VEEVA SYSTEMS INC announced that executives from ASTRAZENECA PLC, BRISTOL MYERS SQUIBB CO, Grünenthal GmbH, NOVO NORDISK A S, Roche Holdings, Inc. and UCB SA are among those featured at Veeva Summit, which presents innovations in AI and data for an agent-based commercial model.
Source:Oct 28, 2026, 13:42 UTC
Eli Lilly said its investigational drug retatrutide was more effective than NOVO NORDISK A S’s Ozempic at lowering blood sugar and reducing weight in a large diabetes study.
Source:Oct 20, 2026, 14:47 UTC
NOVO NORDISK A S shares rose more than 2% on Tuesday.
Source:Oct 20, 2026, 12:50 UTC
NOVO NORDISK A S reported a new analysis showing average weight loss of 25% after 68 weeks among adult women treated with experimental CagriSema.
Oct 19, 2026, 07:25 UTC
China’s National Medical Products Administration approved updated product information allowing NOVO NORDISK A S’s Wegovy semaglutide injection to be stored at 2°C–30°C for up to 48 hours before first opening during distribution to patients.
Oct 15, 2026, 06:48 UTC
China’s National Medical Products Administration approved NOVO NORDISK A S’s application to add an indication for Awiqli (insulin icodec and semaglutide injection) for adults with type 2 diabetes inadequately controlled on oral glucose-lowering medicines.
Source:Oct 14, 2026, 14:12 UTC
The Center for Addiction Science, Policy and Research and the Allegheny County Department of Human Services plan to launch a trial testing Wegovy among adults with substance use disorders and high risk of criminal-justice involvement.
Source:Oct 13, 2026, 22:45 UTC
NOVO NORDISK A S shares closed at $38.06, down 1.35% from the previous trading session.
Source:Oct 10, 2026, 11:30 UTC
NPR reported finding more than 1,000 adverse-event reports of optic neuropathy linked to GLP-1 drugs in the FDA database since 2024, among nearly 190,000 reports about the drugs.
Oct 10, 2026, 11:30 UTC
Todd Engel filed a lawsuit against NOVO NORDISK A S alleging that it failed to warn patients and doctors about the risk of NAION from Ozempic.
Oct 7, 2026, 22:46 UTC
NOVO NORDISK A S shares rose 1.95% to $38.26 at the latest trading-day close.
Source:Oct 5, 2026, 13:10 UTC
The U.S. Food and Drug Administration extended its review of Novo Nordisk's experimental hemophilia A drug due to ongoing remediation work at a manufacturing facility.
Source:Oct 2, 2026, 20:53 UTC
The US FDA informed Novo Nordisk that its Biologics License Application review for denecimig for the treatment of haemophilia A remains ongoing, with no new timeline communicated for regulatory action.
Oct 2, 2026, 13:11 UTC
Boehringer Ingelheim and Zealand Pharma reported that their obesity drug helped diabetes patients lose up to 13.1% of their body weight, a result seen as disappointing.
Source:Oct 2, 2026, 06:44 UTC
Eli Lilly and Co reported promising mid-stage data for EloraTZP, an experimental obesity treatment combining eloralintide and tirzepatide, which produced weight loss of up to 23.3% after 48 weeks in overweight or obese patients with type 2 diabetes.
Sep 30, 2026, 17:00 UTC
A large Nordic registry study presented at the European Association for the Study of Diabetes annual meeting in Milan found no increased pancreatic cancer risk among semaglutide users with type 2 diabetes.
Source:Sep 30, 2026, 09:50 UTC
Romania announced a research collaboration with Novo Nordisk on an oral formulation of Wegovy.
Source:Sep 29, 2026, 07:57 UTC
Ibec published a report finding that European firms operating in Ireland directly employ 280,000 people and contribute €16 billion annually in wages to the Irish economy.
Source:Sep 29, 2026, 07:15 UTC
Danish pharmaceutical company Novo signed an exclusive agreement with Chinese company Jiangsu Hengrui Pharmaceuticals for rights to develop, produce and sell a weight loss pill in all markets except China, Hong Kong, Macau and Taiwan.
Sep 29, 2026, 04:29 UTC
Hengrui Medicine signed a licensing agreement with Novo Nordisk for HRS-1596.
Sep 25, 2026, 11:30 UTC
Federal cases alleging that GLP-1 medicines from Novo Nordisk and Eli Lilly caused non-arteritic anterior ischaemic optic neuropathy (NAION) were consolidated into a multidistrict litigation in Pennsylvania, with 216 actions pending as of September 1, 2026.
Source:Sep 25, 2026, 04:51 UTC
Novo Nordisk signed a drug technology agreement with Sweden's Nanexa worth EUR 1.165 billion.
Sep 25, 2026, 03:19 UTC
Fortune magazine released its 2026 'Change the World' list of 50 companies spanning environmental protection, health and safety, access to resources for vulnerable groups, and economic development opportunities.
Source:Sep 24, 2026, 16:15 UTC
The FDA warned Houston-based Empower Pharmacy that it violated federal law by mass-copying patented GLP-1 weight-loss drugs in inordinate amounts, giving the pharmacy an opportunity to comply.
Source:Sep 24, 2026, 14:56 UTC
United Laboratories International Holdings received a US$9 million milestone payment from Novo Nordisk for the global Phase II clinical trial of UBT251.
Source:Sep 23, 2026, 15:15 UTC
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued positive opinions recommending EU approval for Novo Nordisk's rare disease drugs Frehemgo and Sogroya.
Source:Sep 23, 2026, 04:13 UTC
Novo Nordisk CEO Mike Doustdar said the company is open to upgrading its New York listing to raise its profile in the United States.
Source:Sep 21, 2026, 16:00 UTC
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for Novo Nordisk's Sogroya for the treatment of idiopathic short stature in the EU.
Source:Sep 17, 2026, 11:06 UTC
Novo Nordisk reported that its drug DeneciMig showed good tolerability in patients switching from eculizumab.
Source:Sep 10, 2026, 06:22 UTC
Novo Nordisk's long-acting growth hormone somapacitan injection (brand name Sogroya) received approval in China for three new pediatric indications: Noonan syndrome-associated growth failure, idiopathic short stature, and short stature in children born small for gestational age, all for patients aged 2.5 years and older.
Source:Aug 29, 2026, 22:45 UTC
Thousands of individual lawsuits have been filed in the U.S. District Court for the Eastern District of Pennsylvania against Novo Nordisk and Eli Lilly, alleging that they failed to adequately warn patients about gastrointestinal risks (gastroparesis, ileus, intestinal blockage) associated with their diabetes and obesity drugs Ozempic, Wegovy, Mounjaro, and Zepbound.
Source:
Page 1Next →